Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

shire_image_4

Shire gets positive opinion from EMA on rare gastrointestinal disease treatment

May 27, 2016 Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, Revestive, Shire, gastrointestinal, paediatric, short bowel syndrome, treatment

Shire (LSE: SHP) has announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for …
News
roche__tree

Roche says comparison study for its Gazyva/ Gazyvaro showed superior progression-free survival in follicular lymphoma

May 27, 2016 Medical Communications, Research and Development Comparison Study, Roche, drug trial, follicular lymphoma

Roche (SIX: ROG) on Friday said late-stage comparison trials for its drug to treat a slower form of non-Hodgkin lymphoma …
News

AstraZeneca says NDA for drug to treat hyperkalaemia gets observations from the US FDA

May 27, 2016 Medical Communications, Research and Development AstraZeneca, NDA, US FDA, regulation

UK pharma firm AstraZeneca (LSE: AZN) on Friday said the US Food and Drug Administration (FDA) has issued a complete …
News

AstraZeneca says its Faslodex shows superiority in comparison study for advanced breast cancer

May 27, 2016 Medical Communications, Research and Development, Sales and Marketing AstraZeneca, breast cancer, comparision study, drug trial

UK drugmaker AstraZeneca (LSE: AZN) on Friday said late-stage comparison trials for its drug to treat advanced breast cancer showed …
News
eli_lilly_logo

Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance

May 26, 2016 Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer

The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …
News
janssen_latest_logo_on_sign

Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials

May 26, 2016 Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial

Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials.  The company said a significant …
News
lab

Shares at Sarepta Therapeutics jump after FDA delay in drug approval review

May 26, 2016 Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, Sarepta Therapeutics, approval, delay, delayed announcement, muscular dystrophy, sarepta, treatment

Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares after the US Food and …
News

US FDA committee recommends approval of Sanofi’s combination therapy for type 2 diabetes

May 26, 2016 Research and Development, Sales and Marketing

French drug firm Sanofi (Euronext: SAN) said the US Food and Drug Administration (FDA) advisory committee has recommended the approval …
News
sanofi_hq__boetie_hall

Sanofi makes move to remove Medivation board; Medivation hits back

May 25, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medivation, Sanofi, removal of board, takeover

Sanofi (NYSE: SNY) has taken their proposed takeover of Medivation (NASDAQ: MDVN) up several notches, with the French company filing …
News
gilead-sciences

Gilead names Kevin Young new chief operating officer

May 25, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead

Gilead Sciences (NASDAQ: GILD) has announced two new senior appointments, including Kevin Young as its new chief operating officer. Martin …
Appointment
lilly_entrance_web

Eli Lilly showcases emerging pipeline to investors

May 25, 2016 Research and Development Eli Lilly, investors, lilly, pipeline, research and development

Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 …
News

Monsanto rejects Bayer’s $62 billion offer

May 25, 2016 Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto

World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) …
News
novo_flag

FDA committee unanimously recommends Novo Nordisk diabetes combo, IDegLira

May 25, 2016 Research and Development, Sales and Marketing FDA, Novo Nordisk, Panel, Tresiba, Victoza, committee, ideglira, recommendation, staff

Novo Nordisk has announced that a US Food and Drug Administration (FDA) advisory committee has unanimously recommended IDegLira, a type-2 …
News

Nice recommends three drugs to treat diabetes

May 25, 2016 Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …
News

GSK says asthma drug Breo shows superior results over standard care in major study

May 24, 2016 Research and Development, Sales and Marketing COPD, GSK, asthma, breo, drug trial

UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026